Sunday, December 16, 2012

Stevia Corp (STEV) Provides Profit Guidance

Stevia Corp (STEV) Provides Profit Guidance

Company Expects to Generate First Quarterly Profit in 2013



INDIANAPOLIS, IN--(Marketwire - Dec 13, 2012) - Stevia Corp. ( OTCQB : STEV ) ("Stevia Corp" or the "Company"), a farm management company focused on the economic development of stevia, the fastest growing product in the alternative sweetener sector, is pleased to announce the expansion of its commercialization phase and first major crop harvest expected in Vietnam during first quarter of 2013.
Stevia Corp expects crop harvests in Vietnam to top 1,000 tons by March of 2013. Based on its forecasted sales price and costs, the Company believes this will produce more than $2 million of revenue and its first quarterly profit. This follows the first revenue reported by the Company this year of $112,517 for the quarter ended September 30, 2012.
George Blankenbaker, Stevia Corp President, comments, "This will again signify another major milestone achieved well ahead of schedule. This, together with our joint venture operations in China launched last quarter, will begin a solid foundation for the company to continue scaling its business model and target significant revenue and profit growth during calendar year 2013 provided we also achieve certain capital requirements."
Mr. Blankenbaker also added, "Now that we are well into our commercialization phase, we also have plans to update our website and provide a picture gallery and possibly a blog so that the public can more easily track our developments and experience our growth with us. We are excited about the rapid pace of developments and believe it is important to involve our shareholders. We expect to complete the first phase in January, so this is something that our investors can also be looking forward to for the New Year."
Further details of the Company's business, finances, appointments and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information visit: www.steviacorp.us.
About Stevia Corp. ( OTCQB : STEV )
Stevia Corp. is a farm management company focused on best practice agronomic competency in order to deliver high-value stevia through proprietary plant breeding, excellent agricultural methodologies and innovative post-harvest techniques. To date, the Company has acquired two grower supply contracts and three nursery fields in Vietnam. For more information visit: www.steviacorp.us.

About the Stevia Industry SectorWithin two years of the USA market opening, Nielsen-based retail consumption data indicated almost $1 billion of retail sales for the sector. In 2010, stevia products were launched across thirty-five countries and in 38 categories. Zenith International estimates worldwide sales of stevia extract reached 3,500 tons in 2010 with an overall market value of $285 million and forecasts the global market for stevia will reach 11,000 tons by 2014 requiring the tripling of stevia leaf production at the farm level to keep pace with consumer demand. For more information visit: www.steviacorp.us.
Please read Disclosure/Disclaimer Daily Stock Deals read Research Report

Wednesday, October 24, 2012

Stevia Corp, STEV, Profile, Summary

Stevia Corp. | STEV | Profile | Summary

Stevia Corp. (STEV) is a farm management company focused on Stevia agronomics from plant breeding to good agricultural practices to development of stevia derived products.

Stevia Corp. invests heavily in R&D and IP acquisition and manages its own propagation, nursery, and plantations as well as provides services to contract growers and other industry growers.

The Company was founded to deliver top quality agribusiness solutions in order to maximize the efficient mass production of stevia leaf and stevia derived products. The Company is headquartered in the US with farm operations/R&D in Vietnam, China, and Indonesia and planned operations in the US.
Read the comprehensive analysis: find out the 'Target Price', market dynamics, the opportunity and meet the excellent management team click here , download the full report!


INVESTMENT HIGHLIGHTS

◊ Opportunity to invest in an early development stage, vertically-integrated stevia farm management company in an emerging, high growth market

◊ The Company plans to be a “one stop shop” agribusiness solutions provider offering the full spectrum of farm management services

o Operate its own plantations, manage contract farms, and service industry growers (read Executive Summary)
o Expects to achieve positive EBITDA by the second quarter of 2013, growing to $3mm in annualized EBITDA by the end of 2013
o Positioned to become a global leader in the stevia industry that maximizes the efficient mass production of stevia leaf and stevia derived products
o Fastest growing product in the alternative sweetener market with 6,000 products across 35 countries
o Expected to eventually replace 20% of the sugar segment of global sweeteners or a $10 billion market opportunity


◊ Our valuation analysis results in a target price of $1.20 per share which represents significant upside of over 4 times the current stock price (see Valuation)

◊ The Company recently secured $500,000 in an equity private placement
and has access to $20 million from Southridge Partners.

◊ Global sweetener market is a $60 billion dollar industry! See the company's growth plans, the advantages of Vertically Integrated Supply Chain and much more...full free report

MANAGEMENT TEAM

Strong Global Executive Team with highly recognized leadership skills, expertise and decades of experience in Three Continents, Four vibrant economic regions of the world (The United States, Europe, Latin America and Asia-Pacific).

George S. Blankenbaker (President)
Mr. Blankenbaker has been leading the development of high Reb-A Stevia farming in Vietnam, where he imported the Morita variety to trial in 2008 and in 2009 signed a contract to supply stevia leaf to PureCircle, the industry's leading refiner. Mr. Blankenbaker first became involved in commercial agriculture in 2002 when he began working with the Agri-Food Veterinary Authority of Singapore (AVA) to provide strategically important food supplies to Singapore. Prior to that Mr. Blankenbaker co-wrote and co-presented a bid for the U.S. Navy Subsistence Prime Vendor (SPV) Contract valued at USD $197 million covering three zones of Japan, Singapore, and Diego Garcia. The contract was awarded in 2002 and the Singapore and Diego Garcia portion is currently supported by the Rong-Yao group, a partner company based in Singapore.

During the 1990s Mr. Blankenbaker was the Managing Director of a foodservice equipment company servicing South East Asia and was a partner of a holding company that established the first broadline foodservice distribution facility in Singapore which was also the first food distribution facility in Singapore to achieve both ISO 9000 and HACCP certification. Mr. Blankenbaker also traded commodities and was an independent consultant and analyst for Standard Chartered Bank and Reuters and was on the implementation team that established Globex in Singapore linking the Singapore International Monetary Exchange with the Chicago Board of Trade. Read more...

Rodney L. Cook (Director)

Dr. Pablo Erat (Director)

Thomas Ong (Director of Operations, Asia)

Dr. Zhang Ji (Chief Technical Advisor)

Dr. Nguyen Van Dan
(Technical Advisor – Vietnam R&D and Propagation Center)

Vincent Tan Meng Sheong (Director of Operations, China)

click here for Management Bios


Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Wednesday, September 26, 2012

Yukon-Nevada Gold,YNG,YNGFF, Profile, Summary

Yukon-Nevada Gold| YNG |YNGFF | Profile | Summary

Yukon-Nevada Gold Corp is listed on the Toronto Stock Exchange (YNG.TO)
and trades on the OTC/Pinksheets under the symbol YNGFF.

Jerritt Canyon, the Company's flagship project, is located in northern Nevada. The Company is currently focused on modernizing the milling facility and emission control systems. The Company is striving to reach a point of renewed profitability accompanied by a significantly reduced environmental impact. Ongoing permitting at Starvation Canyon, Nevada will allow the Company, in the future, to realize an increase in the production of gold ounces at Jerritt Canyon.

The Company is focused on bringing its wholly owned Ketza River property back into production from the Manto Gold Zones and permitting is underway. The Ketza River Property includes the Ketza River mine, which, from 1987 to 1990, produced 98,000 oz of gold and by-product silver from 340,000 tons of ore.


    1. Jerritt Canyon - historical production of approximately 8 million oz gold since 1981
+ 100% owned.
+ Permitted and Producing.
+ Current Reserve & Resource includes: 374,800 oz Proven, 686,000 oz Probable, 1.03M oz Measured & 1.29M oz Indicated.
+ Mill engineered capacity of 6,000 tpd of which 5,280 tpd is currently permitted.

    2. Ketza River - historical production of 98,000 oz of gold and by-product silver between 1988 - 1990
+ 100% owned.
+ Current Resource includes: 29,000 oz Measured and 388,700 oz Indicated.
+ Site infrastructure well developed.
+ Permitting in progress for mine/mill re-start.

Deutsche Bank invested $40M in equity and $140M gold forward sale.


Planned mine includes 9 open pits and
2 underground declines

+ 83% of the oz to be mined will come from the open pits.
+ Estimated mining rate of 50,000 tpd for the first 2 years and 20,000 tpd in the 3rd year from the open pits.
+ An additional 500 tpd will come from underground mining.

A total of 41% of the measured and indicated recoverable resource ounces are hosted in oxide ores which have a gold recovery of 90%; whereas the other 59% of the measured and indicated recoverable, resource ounces are hosted in sulfide or mixed sulfide+oxide ores that generally have Au recoveries of 70%.

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Saturday, September 8, 2012

HOKU, Hoku Corporation, Profile, Summary

Hoku Corporation | HOKU | Profile | Summary
Hoku Corporation (HOKU) is a solar products and services company operating two businesses: Hoku Materials and Hoku Solar. Hoku Materials manufactures, markets and sells polysilicon for the solar industry from its plant currently under construction in Pocatello, Idaho. Hoku Solar is a leading provider of commercial solar power, offering turnkey PV systems and project development services.

Hoku Solar
Hoku Solar – HOKU - is a leading provider of investment-grade solar power, offering project development services, turnkey PV system integration and asset management for solar energy facilities.
Hoku Solar focuses primarily on the commercial and industrial solar market segment, providing large-scale rooftop or ground-mounted PV arrays for businesses, institutions and government clients. We have proven experience with specialty and technical solar products, including third party financed purchase power agreements (PPAs), and building integrated PV. Hoku is also increasingly engaged in the multi-megawatt utility scale market, both as a project developer and as an EPC service provider.
Hoku Solar is active in Hawaii, and is expanding its project development business to other U.S. markets.
Hoku Solar Services

Turnkey PV Integration
Hoku Solar is a full-service solar industry EPC contractor, providing its customers with turnkey engineering, procurement, and construction services for investment-grade PV.

Hoku Solar primarily serves commercial and industrial rooftop customers, large real estate portfolio holders and developers, general contractors, and government and institutional clients.

With proven experience in the Hawaii market, Hoku can deliver a full range of commercial systems, ranging from individual rooftop arrays to multi-megawatt ground-mounted systems.
Project Development
With our unique design and development service offering, Hoku Solar is positioned to bring large-scale and portfolio PV projects to life, whether as lead developer, or as a complement to an existing project team.
Hoku Solar has proven experience at every stage of the PV development cycle – from feasibility studies to commissioning and take-out financing – and we tailor our services to the individual needs of the project. So, whether Hoku is leading the development itself, or contributing to a broader effort, we are focused on scaling up solar in the U.S.
Contact us today and let us put our experience to work for you.
Asset Management
Underperforming solar arrays are underperforming investments. Hoku Solar has the engineering, technical and operational experience to help ensure your target returns are achieved.

We offer customized operations and maintenance programs for a wide variety of commercial systems, each designed to enhance overall system performance and reliability. From system assessment to preventative and corrective maintenance and monitoring, let Hoku Solar’s asset management team help guarantee your PV system’s long-term performance.
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!® we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.
If you want to get your company profiled or have any questions, please don't hesitate to contact the Editor [@ ] OxBridgeResearch.com

Sunday, September 2, 2012

Romney's Tax Secret Revealed! How to Convert Ordinary Income into Capital Gains.

The New York attorney general is investigating whether some of the nation’s biggest private equity firms have abused a tax strategy in order to slice hundreds of millions of dollars from their tax bills, according to executives with direct knowledge of the inquiry.
Enlarge This Image

Andrew Harrer/Bloomberg News
The Washington office of the Carlyle Group, which The Carlyle Group has stated in regulatory filings that their partners have not diverted management fees into investments in their funds.
Enlarge This Image

Evan McGlinn for The New York Times
Bain offices in Boston. According to financial statements, Bain partners saved more than $200 million in federal income taxes and more than $20 million in Medicare taxes.
Readers’ Comments
Share your thoughts.
Post a Comment »
Read All Comments (218) »
The attorney general, Eric T. Schneiderman, has in recent weeks subpoenaed more than a dozen firms seeking documents that would reveal whether they converted certain management fees collected from their investors into fund investments, which are taxed at a far lower rate than ordinary income.
Among the firms to receive subpoenas are Kohlberg Kravis Roberts & Company, TPG Capital, Sun Capital Partners, Apollo Global Management, Silver Lake Partners and Bain Capital, which was founded by Mitt Romney, the Republican nominee for president. Representatives for the firms declined to comment on the inquiry.
Mr. Schneiderman’s investigation will intensify scrutiny of an industry already bruised by the campaign season, as President Obama and the Democrats have sought to depict Mr. Romney through his long career in private equity as a businessman who dismantled companies and laid off workers while amassing a personal fortune estimated at $250 million.
Some executives at the firms said they feared that Mr. Schneiderman, a first-term Democrat with ties to the Obama administration, was seeking to embarrass the industry because of Mr. Romney’s roots at Bain. Others suggested that the subpoenas, which were issued by the attorney general’s Taxpayer Protection Bureau, might be part of an effort to recover more revenue for New York under state tax law. The attorney general’s office does not have the power to enforce federal tax laws.
A spokesman for Mr. Schneiderman declined to comment.
The tax strategy — which is viewed as perfectly legal by some tax experts, aggressive by others and potentially illegal by some — came to light last month when hundreds of pages of Bain’s internal financial documents were made available online. The financial statements show that at least $1 billion in accumulated fees that otherwise would have been taxed as ordinary income for Bain executives had been converted into investments producing capital gains, which are subject to a federal tax of 15 percent, versus a top rate of 35 percent for ordinary income. That means the Bain partners saved more than $200 million in federal income taxes and more than $20 million in Medicare taxes.
The subpoenas, which executives said were issued in July, predated the leak of the Bain documents by several weeks and do not appear to be connected with them. Mr. Schneiderman, who is also co-chairman of a mortgage fraud task force appointed by Mr. Obama, has made cracking down on large-scale tax evasion a priority of his first term.
As a retired partner, Mr. Romney continues to receive profits from Bain Capital and has had investments in some of the funds that documents show used the tax strategy.
The campaign issued a statement saying that Mr. Romney did not, however, benefit from the practice. “Investing fee income is a common, accepted and totally legal practice,” said R. Bradford Malt, a lawyer for Mr. Romney who manages his family’s investments and trusts. “However, Governor Romney’s retirement agreement did not give the blind trust or him the right to do this, and I can confirm that neither he nor the trust has ever done this, whether before or after he retired from Bain Capital.”
Managers at a typical private equity firm or hedge fund collect from their investors management fees based on the size of the fund. But most of their compensation comes as a share of the profits earned by the fund. The Internal Revenue Service allows those profits to be considered “carried interest,” taxed at the capital gains rate typically reserved for investments.
The tax strategy used by Bain and other firms to convert management fees — the compensation normally taxed as ordinary income — into capital gains is known as a “management fee waiver.” The strategy is widely used within the industry: 40 percent of the 35 buyout firms based in the United States surveyed in 2009 by Dow Jones said their partners used at least some of the firm’s fees to make investments in their funds.
But some prominent firms appear to avoid the practice. The Carlyle Group and Blackstone Group have stated in regulatory filings that their partners have not diverted management fees into investments in their funds.
In the varied world of private equity, some firms may have lawyers who are not aware of the strategy or have steered their clients away from it, said a lawyer at one firm who has used the strategy for his clients. Others, he said, may not have the operational capabilities to handle the complex transactions.
Apollo Global Management, the buyout firm co-founded by Leon Black and now publicly traded, is among those that use the conversion strategy. Between 2007 and 2011, Apollo converted more than $131 million in fees into investments in its funds, according to S.E.C. filings. A spokesman for the firm declined to comment.
Likewise, K.K.R. converted more than $180 million in fees between 2007 and 2009, according to its filings. Kristi Huller, a spokeswoman for the firm, declined to comment about any regulatory matter, but said in an e-mail that K.K.R. had not used the tax strategy “for the past few years.”
Other firms that received subpoenas include Clayton, Dubilier & Rice; Crestview Partners; H.I.G. Capital; Vestar Capital Partners; and Providence Equity Partners. Representatives for all these firms declined to comment.
Tax lawyers have justified the arrangements by arguing that converting the management fees into carried interest, which could lose some or all of its value if a fund does poorly, entitles the managers to the lower capital gains rate, which is intended to help mitigate the risks taken by investors.
“They’re risking their management fee — they’re giving up the right to that management fee in any and all events,” said Jack S. Levin, a finance lawyer whose firm has represented Bain on some matters. Mr. Levin said he did not consider the practice risky or even aggressive.
“The I.R.S. has known that private equity funds have been doing this for 20 years,” he said.
In 2007, the agency began taking a closer look at suspected tax abuses at hedge funds and private equity firms. In a statement at the time, an I.R.S. spokesman said that management fee conversions were among several “areas of possible noncompliance.” But no formal ruling appears to have emerged.
Some private equity firms take what tax experts consider a less aggressive approach to the conversions, waiving fees on all of a given fund’s investments over the lifetime of the fund, which can be 10 years.
But other firms choose which funds or even which particular investments to waive fees on frequently, like every year or every quarter. Such arrangements may allow the executives to apply the waiver only when they believe their funds are more likely to appreciate in value, substantially reducing their investment risk.
Mr. Schneiderman is also looking at whether private equity executives treated management fees as a return of invested capital — potentially escaping taxation entirely — or deferred payouts of the converted fees in ways that improperly reduced their tax liabilities.
Executives at three of the firms subpoenaed by Mr. Schneiderman, who asked for anonymity because they were bound by confidentiality agreements, said that disclosures to their investors clearly stated that the waived fees were allocated equally to all the investments in a fund.
The leaked documents show that Bain has in recent years waived management fees in at least eight private equity and other funds, including one formed as early as January 2002. The documents stated that Bain executives had the right to decide either annually or each quarter whether to waive some or all of their management fees; they also had the ability to convert the waived fees into investments in particular companies held by the funds.
Victor Fleischer, a law professor and finance expert at the University of Colorado who has been critical of the tax rules for private equity firms, said he believed Bain had waived management fees into investments with so little risk that the arrangement would not qualify for the capital gains rate if challenged by the I.R.S.
“There is a tension between economic risk and tax risk that is supposed to be inversely proportional,” Mr. Fleischer said. “The way Bain set it up there’s not much risk at all, so it’s hard to see how this income should receive capital gains treatment.”

Michael Luo contributed reporting.
Courtesy: New York Times
OxBridgeResearch

A123 Systems, AONE, Profile, Summary

A123 Systems |AONE | Profile | Summary

A123 Systems – AONE - develops and manufactures advanced Nanophosphate® lithium iron phosphate batteries and energy storage systems. The company’s technology enables customers to commercialize innovative products for the transportation, electric grid, commercial and government markets.

A123's proprietary Nanophosphate technology is built on novel nanoscale materials initially developed at the Massachusetts Institute of Technology. The company has spent more than $2 billion dollars on development and large scale manufacturing plants with global ambitions.
IronPhosphate Battery Technology
A123’s high-performance Nanophosphate® lithium iron phosphate (LiFePO4) battery technology delivers high power and energy density combined with excellent safety performance and extensive life cycling in a lighter weight, more compact package. Our products have low capacity loss and impedance growth over time, allowing our systems to meet end-of-life power and energy requirements with minimal pack oversizing.
Lithium Ion Battery Technology
A123’s next-generation Nanophosphate EXT™ lithium ion battery technology improves power capability at low temperature and life at high temperature, potentially reducing or eliminating the need for costly thermal management.
By extending the capabilities of our core Nanophosphate® technology over a wider temperature operating range, Nanophosphate EXT is expected to deliver increased performance and reliability while minimizing complexity and reducing total cost of ownership (TCO) over the life of the battery system for a number of applications, including micro hybrid vehicles, electric vehicles, telecommunications backup and military systems, among others.
Energy Storage Systems
A123 Systems excels at designing and manufacturing fully-integrated battery systems that help enable our customers to take new products from concept to commercialization. A123 has extensive engineering experience in developing and implementing advanced components, software, electronics, thermal management and battery management systems for innovations in battery system design. We provide complete system design and integration services and develop optimized systems that meet our customer’s performance requirements, including power, safety, life, and energy, while meeting size, weight and cost targets.
The Opportunity
The recession in the United States and European Economic crisis resulted in slower than expected demand for the Electric Vehicles. The company is poised to benefit when the global economic conditions improve, it has invested hundreds of millions in R&D and established long term relationships with leading OEMs and built a network of charging stations.
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Hemispherx Biopharma, HEB, Profile, Summary

Hemispherx Biopharma | HEB | Profile | Summary
Hemispherx Biopharma (HEB) is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental immunotherapeutics/antivirals Ampligen®.
Hemispherx’s platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in New Brunswick, New Jersey.

ALFERON
Alferon N Injection® is the company's registered trademark for its injectable formulation of Natural Alpha Interferon, and is approved by the FDA for a category of STD infection.  Alferon N Injection® (interferon alfa-n3 human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon.
Alferon LDO® (Low Dose Oral) is a new experimental drug delivery platform for the Company’s highly purified, natural source alpha interferon.
ALFERON N Injection® is the only highly purified, natural-source, multispecies alpha interferon product currently sold in the U.S. and is also approved for sale in Argentina.
Clinically Effective:
All warts disappeared in 54% of patients.3
No recurrence in 76% of complete responders at follow-up.3
Completely cleared 73% of all treated warts.3,4
No human antibodies to interferon alfa-n3 detected in clinical trails.3,4
Provides a spectrum of multiple alpha interferon subtypes.1,

What's in the Pipeline?
Ampligen® (poly I:poly C12U) is a synthetic specifically configured double-stranded RNA containing regularly occurring regions of mismatching.  Ampligen® and Oragens® experimental nucleic acids are being developed for the potential treatment of globally important viral diseases and disorders of the immune system including HPV, HIV, Chronic Fatigue Syndrome (CFS), Hepatitis and influenza.

Watch This!
On July 31, 2012 Hemispherx submitted its complete response to the FDA’s Complete Response Letter in support of Ampligen®’s New Drug Application for Chronic Fatigue Syndrome (“CFS”).
Its too early to tell what the FDA's response would be, however, the response from investors has been very positive. We alerted our members and followers last week and we believe this company should be on your radar!
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.